Online Inquiry

Global Services. (Creative Biolabs Authorized)

Lentiviral Integration Site Analysis (ISA) & Insertion Mutagenesis Safety Evaluation Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

While lentiviral vectors are indispensable in gene and cell therapy, their semi-random genomic integration poses significant risks of insertional mutagenesis and oncogenic transformation. To address these critical safety concerns, we provide a comprehensive Lentiviral Integration Site Analysis (ISA) & Insertion Mutagenesis Safety Evaluation. Utilizing advanced high-throughput sequencing and specialized bioinformatics, this service precisely maps integration sites and monitors clonal dynamics with exceptional resolution. By delivering highly sensitive, regulatory-compliant data, we empower you to confidently assess therapeutic safety and accelerate their clinical translation.

Introduction

Lentiviral integration site profiling constitutes a critical quality attribute in CAR-T cell therapy, as the precise genomic location of vector insertion directly governs transgene expression stability and clonal dynamics within engineered T-cell products. Insertion mutagenesis, the potential dysregulation of host genes adjacent to or downstream of the integration locus, poses a well-documented risk of aberrant clonal expansion and leukemogenesis, necessitating rigorous safety surveillance.

Fig.1 The technical landscape surrounding the detection of integration sites for retroviruses and their derived vectors. (OA Literature) Fig.1 The methodological landscape for identifying integration sites of retroviruses and retroviral vectors.¹

Our Service

Our service delivers high-resolution genomic mapping of vector integration profiles. By precisely quantifying clonal dynamics and identifying insertional genotoxicity near critical oncogenes, we mitigate insertional mutagenesis risks. We provide robust, regulatory-ready safety datasets and expert bioinformatics to confidently accelerate your cell therapy toward successful IND filing.

What We Can Offer

We provide a comprehensive, tiered lentiviral integration site analysis portfolio, spanning validated PCR-based genotyping, NGS-enhanced full-genome coverage, and single-molecule ultra-sensitive detection, to deliver precise insertion mutagenesis safety evaluation across all stages of translational gene therapy development.

Featured services of RCL regulatory compliance assay (VSV-G / Wild-Type) at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Preclinical/In vitro Samples: Target cell lines, primary cells transduced with lentivirus, or animal model tissues.
Clinical Samples: Patient peripheral blood mononuclear cells (PBMCs), whole blood, bone marrow, or relevant biopsy tissues.
Lentiviral Vector Information.

Key Steps:

Workflow of RCL regulatory compliance assay (VSV-G / Wild-Type) at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Quality Control & Raw Data.
Integration Site List.

Key Advantages

Single-Base Resolution and Ultra-High Sensitivity: We offer single-nucleotide precision in mapping viral integration sites and achieve exceptional sensitivity capable of detecting rare insertional events within hundreds of thousands of cells for early risk prediction.
Quantitative Tracking of Clonal Dominance and Evolution: We quantify clonal abundance and perform longitudinal tracking across multiple time points to provide early warnings against abnormal clonal expansion.
Comprehensive Onco-Risk Profiling and Gene Annotation: We automatically cross-reference integration sites with databases of proto-oncogenes, tumor suppressors, and common insertion sites (CIS) to proactively mitigate the risk of insertional oncogenesis before cellular infusion.
Data-Driven Optimization of Vector Design and Bioprocessing: We analyze large-scale integration datasets to decipher vector integration preferences, thereby guiding the optimization of vector architecture and transduction parameters to minimize genotoxicity from the source.

FAQ

Q1: Does your safety evaluation cross-reference known oncogenes?

A1: Yes. Our automated annotation pipeline cross-references all identified integration sites with updated cancer gene databases. We specifically risk-score any insertions occurring of known proto-oncogenes, tumor suppressor genes, or microRNAs involved in hematopoiesis and oncogenesis.

Q2: Can this service be used for longitudinal patient monitoring during clinical trials?

A2: Yes. We offer specialized longitudinal tracking services tailored for Phase I/II/III clinical trials. By analyzing peripheral blood or bone marrow samples collected from patients at multiple post-infusion time points, we can monitor the clonal evolution and ensure early detection of any aberrant clonal expansion.

Why Choose Us?

We deliver industry-leading, high-resolution ISA services powered by advanced LAM-PCR and NGS technologies. By providing precise single-base mapping, rigorous clonal dominance tracking, and comprehensive oncogene risk annotation, we ensure your gene and cell therapy products meet the most stringent global regulatory standards for clinical safety and efficacy.

Customer Reviews

"In hematopoietic stem cell (HSC) gene therapy, insertion mutagenesis is a critical safety bottleneck. We used this service to analyze the clonal diversity of our lentivirus-transduced HSCs before and after transplantation in animal models. Their high-throughput sequencing approach combined with bioinformatics pipelines delivered highly accurate indices and coefficients. This allowed us to rigorously prove that our vector modifications successfully prevented clonal dominance and insertional oncogenesis." Dr. K* T*.

"During our CAR-T clinical trials, monitoring the clonal expansion and safety of the infused cells was our top priority. This Lentiviral Integration Site Analysis (ISA) service provided us with longitudinal mapping of integration sites with incredible genomic resolution. They were able to detect and quantify dominant clones and evaluate if any insertions occurred near known oncogenes." Dr. C* S*.

How to contact us?

As leaders in lentiviral ISA and insertion mutagenesis safety, we provide expert end-to-end support from advanced sequencing to precise risk classification. Our team offers rapid turnaround and clear regulatory guidance. Let's discuss your project needs and timeline. Reach out today for a consultation and detailed quote—we're ready to move your program forward.

Reference

Kochergin-Nikitsky, Konstantin et al. "Methodological landscape in the field of integration site identification of retroviruses and retroviral vectors." Frontiers in bioengineering and biotechnology vol. 13 1708724. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fbioe.2025.1708724.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.